Hei Y J, Chen X, Pelech S L, Diamond J, McNeill J H
Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Diabetes. 1995 Oct;44(10):1147-55. doi: 10.2337/diab.44.10.1147.
The mitogen-activated protein (MAP) kinases and ribosomal S6 protein kinases in the skeletal muscle of insulin-resistant long-term (2 and 6 months' duration) diabetic rats were investigated to understand further the changes in insulin intracellular signaling pathways that accompany diabetes. The effects of insulin-mimetic vanadium compounds on the activity of these kinases were also examined. In the insulin-resistant 2-month diabetic rats, the basal activities of MAP kinases were relatively unchanged, while the basal activities of S6 kinases were significantly increased. Intravenous injection of insulin moderately activated both the 42-kDa MAP kinase (p42mapk) and a 44-kDa MAP kinase (p44erk1) in the 2-month control rats but not in the 2-month diabetic rats. Insulin treatment markedly stimulated the activity of a novel 31-kDa S6 kinase and the previously described 90-kDa ribosomal S6 kinase encoded by one of the rsk genes (p90rsk) in the 2-month control rats, while the effect was substantially reduced in the diabetic rats. In the 6-month diabetic rats, the basal phosphotransferase activities of both MAP kinases were depressed threefold or greater. This correlated with reductions in the amount of immunoreactive p42mapk and p44erk1 proteins in extracts from the diabetic rats. The basal activity of the 31-kDa S6 kinase activity was also reduced fourfold in the 6-month diabetic rats. Treatment of the 2-month diabetic rats with vanadyl sulfate resulted in euglycemia, prevented the increase in the basal activity of S6 kinase, and improved the activation of S6 kinase by insulin.(ABSTRACT TRUNCATED AT 250 WORDS)
为了进一步了解糖尿病伴随的胰岛素细胞内信号通路变化,研究了胰岛素抵抗的长期(2个月和6个月病程)糖尿病大鼠骨骼肌中的丝裂原活化蛋白(MAP)激酶和核糖体S6蛋白激酶。还检测了胰岛素模拟钒化合物对这些激酶活性的影响。在胰岛素抵抗的2个月糖尿病大鼠中,MAP激酶的基础活性相对未变,而S6激酶的基础活性显著增加。静脉注射胰岛素可适度激活2个月对照大鼠中的42 kDa MAP激酶(p42mapk)和44 kDa MAP激酶(p44erk1),但在2个月糖尿病大鼠中则不然。胰岛素处理显著刺激了2个月对照大鼠中一种新的31 kDa S6激酶和由rsk基因之一编码的先前描述的90 kDa核糖体S6激酶(p90rsk)的活性,而在糖尿病大鼠中这种作用明显减弱。在6个月糖尿病大鼠中,两种MAP激酶的基础磷酸转移酶活性均降低了三倍或更多。这与糖尿病大鼠提取物中免疫反应性p42mapk和p44erk1蛋白量的减少相关。6个月糖尿病大鼠中31 kDa S6激酶的基础活性也降低了四倍。用硫酸氧钒治疗2个月糖尿病大鼠可导致血糖正常,防止S6激酶基础活性增加,并改善胰岛素对S6激酶的激活。(摘要截短于250字)